Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Nuclear Cardiology
Published in: Journal of Nuclear Cardiology 4/2023

Open Access 08-02-2023 | Vulgar Psoriasis | ORIGINAL ARTICLE

Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study

Authors: Kevin E. Boczar, MD, Rob S. Beanlands, MD, Steven J. Glassman, MD, Jerry Wang, BSc, Wanzhen Zeng, MD, Robert A. deKemp, PhD, Natalie C. Ward, PhD, Christophe A. Fehlmann, MD, George A. Wells, PhD, Jacob Karsh, MD, Girish Dwivedi, MD, PhD, FRACP, FASE, FESC, FSCCT

Published in: Journal of Nuclear Cardiology | Issue 4/2023

Login to get access

Abstract

Aim

The aim of the study was to evaluate the changes in central vascular inflammation measured by FDG PET and myocardial blood flow reserve (MFR) determined by 82Rb PET following therapy with biologic agents for 6 months in patients with psoriatic arthritis (PsA) and/or cutaneous psoriasis (PsO) (group 1) and compare with PsO subjects receiving non-biologic therapy (group 2) and controls (group 3).

Methods and Results

Target-to-background ratio (TBR) by FDG PET in the most diseased segment of the ascending aorta (TBRmax) was measured to assess vascular inflammation. 82Rb PET studies were used to assess changes in left ventricular MFR. A total of 34 participants were enrolled in the study (11 in group 1, 13 in group 2, and 10 controls). A significant drop in the thoracic aorta uptake was observed in the biologic-treated group (ΔTBRmax: − .46 ± .55) compared to the PsO group treated with non-biologic therapy (ΔTBRmax: .23 ± .67). Those showing response to biologic agents maintained MFR compared to who showed no response.

Conclusion

In a cohort of psoriasis patients treated with biologics, FDG uptake in the thoracic aorta decreased over the study period. Patients who demonstrated a significant anti-inflammatory response on FDG PET imaging maintained their MFR compared to non-responders.
Literature
1.
2.
Peluso R, Caso F, Tasso M, Ambrosino P, Dario Di Minno MN, Lupoli R. Cardiovascular risk markers and major adverse cardiovascular events in psoriatic arthritis patients. Rev Recent Clin Trials 2018;13:199‐209.PubMedPubMedCentral
3.
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatol 2013;149:1173‐9.PubMedPubMedCentral
4.
Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch Dermatol 2007;143:1493‐9.PubMed
5.
McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: A 5-yr prospective study. Rheumatology (Oxford) 2003;42:778‐83.PubMed
6.
Daghem M, Newby D. Psoriasis and inflammation more than skin deep. Circ Cardiovasc Imaging 2018;11:e007849.PubMed
7.
8.
Naik HB, Natarajan B, Stansky E, Ahlman MA, Teague H, Salahuddin T, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol 2015;35:2667‐76.PubMedPubMedCentral
9.
Piaserico S, Osto E, Famoso G, Montisci R, De Michieli L, Zanetti I, et al. Long-term prognostic value of coronary flow reserve in psoriasis patients. Atherosclerosis 2019;289:57‐63.PubMed
10.
Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002;105:2708‐11.PubMed
11.
Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818‐24.PubMed
12.
Cocker MS, Spence JD, Hammond R, deKemp RA, Lum C, Wells G, et al. [18F]-Fluorodeoxyglucose PET/CT imaging as a marker of carotid plaque inflammation: Comparison to immunohistology and relationship to acuity of events. Int J Cardiol 2018;271:378‐86.PubMed
13.
Figueroa AL, Abdelbaky A, Truong QA, Corsini E, MacNabb MH, Lavender ZR, et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events. JACC Cardiovasc Imaging 2013;6:1250‐9.PubMed
14.
Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med 2009;50:1611‐20.PubMed
15.
Marnane M, Merwick A, Sheehan OC, Hannon N, Foran P, Grant T, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol 2012;71:709‐18.PubMed
16.
Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol 2013;62:909‐17.PubMed
17.
Mizoguchi M, Tahara N, Tahara A, Nitta Y, Kodama N, Oba T, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011;4:1110‐8.PubMed
18.
Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc Imaging 2010;3:623‐40.PubMed
19.
deKemp RA, Klein R, Beanlands RS. (82)Rb PET imaging of myocardial blood flow-have we achieved the 4 “R”s to support routine use? EJNMMI Res 2016;6:69.PubMedPubMedCentral
20.
Germino M, Ropchan J, Mulnix T, Fontaine K, Nabulsi N, Ackah E, et al. Quantification of myocardial blood flow with (82)Rb: Validation with (15)O-water using time-of-flight and point-spread-function modeling. EJNMMI Res 2016;6:68.PubMedPubMedCentral
21.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheumatism 2006;54:2665‐73.PubMed
22.
Anagnostopoulos C, Almonacid A, El Fakhri G, Curillova Z, Sitek A, Roughton M, et al. Quantitative relationship between coronary vasodilator reserve assessed by 82Rb PET imaging and coronary artery stenosis severity. Eur J Nucl Med Mol Imaging 2008;35:1593‐601.PubMedPubMedCentral
23.
Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS. Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol 2011;30:877‐85.PubMed
24.
Puzenat E, Bronsard V, Prey S, Gourraud PA, Aractingi S, Bagot M, et al. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010;24:10‐6.PubMed
25.
Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur J Nucl Med Mol Imaging 2007;34:1765‐74.PubMed
26.
Chih S, Chong AY, Erthal F, deKemp RA, Davies RA, Stadnick E, et al. PET Assessment of epicardial intimal disease and microvascular dysfunction in cardiac allograft vasculopathy. J Am Coll Cardiol 2018;71:1444‐56.PubMed
27.
Goff KL, Karimkhani C, Boyers LN, Weinstock MA, Lott JP, Hay RJ, et al. The global burden of psoriatic skin disease. Br J Dermatol 2015;172:1665‐8.PubMed
28.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735‐41.PubMed
29.
Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: Cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000‐6.PubMed
30.
Mehta NN, Li R, Krishnamoorthy P, Yu Y, Farver W, Rodrigues A, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis 2012;224:218‐21.PubMedPubMedCentral
31.
Harrington CL, Dey AK, Yunus R, Joshi AA, Mehta NN. Psoriasis as a human model of disease to study inflammatory atherogenesis. Am J Physiol Heart Circ Physiol 2017;312:H867‐73.PubMedPubMedCentral
32.
Maki-Petaja KM, Elkhawad M, Cheriyan J, Joshi FR, Ostor AJ, Hall FC, et al. Anti-tumor necrosis factor-alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012;126:2473‐80.PubMed
33.
Kim BS, Lee WK, Pak K, Han J, Kim GW, Kim HS, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using (18)F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol 2019;80:1322‐31.PubMed
34.
Dey AK, Joshi AA, Chaturvedi A, Lerman JB, Aberra TM, Rodante JA, et al. Association between skin and aortic vascular inflammation in patients with psoriasis: A case-cohort study using positron emission tomography/computed tomography. JAMA Cardiol 2017;2:1013‐8.PubMed
35.
Mehta NN, Shin DB, Joshi AA, Dey AK, Armstrong AW, Duffin KC, et al. Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: A randomized placebo-controlled trial. Circ Cardiovasc Imaging 2018;11:e007394.PubMedPubMedCentral
36.
Bengel FM. Imaging of post-infarct inflammation: Moving forward toward clinical application. Circ Cardiovasc Imaging 2016;9:e004713.PubMed
37.
Li X, Rosenkrans ZT, Wang J, Cai W. PET imaging of macrophages in cardiovascular diseases. Am J Transl Res 2020;12:1491‐514.PubMedPubMedCentral
38.
Tarkin JM, Joshi FR, Rudd JH. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 2014;11:443‐57.PubMed
39.
Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 2014;383:705‐13.PubMed
40.
Fox JJ, Strauss HW. One step closer to imaging vulnerable plaque in the coronary arteries. J Nucl Med 2009;50:497‐500.PubMed
41.
42.
Joseph P, Tawakol A. Imaging atherosclerosis with positron emission tomography. Eur Heart J 2016;37:2974‐80.PubMed
Metadata
Title
Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: A prospective cohort FDG PET study
Authors
Kevin E. Boczar, MD
Rob S. Beanlands, MD
Steven J. Glassman, MD
Jerry Wang, BSc
Wanzhen Zeng, MD
Robert A. deKemp, PhD
Natalie C. Ward, PhD
Christophe A. Fehlmann, MD
George A. Wells, PhD
Jacob Karsh, MD
Girish Dwivedi, MD, PhD, FRACP, FASE, FESC, FSCCT
Publication date
08-02-2023
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 4/2023
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-023-03204-8

Other articles of this Issue 4/2023

Journal of Nuclear Cardiology 4/2023 Go to the issue

Images that Teach

A story of resolved ischemia from anomalous coronary arteries as told by PET/CT

EDITORIAL

Myocardial perfusion reserve by CZT cameras: A journey inside coronary microvascular circulation. Is it time to leave yet?

ORIGINAL ARTICLE

Comparison of the prognostic value of impaired stress myocardial blood flow, myocardial flow reserve, and myocardial flow capacity on low-dose Rubidium-82 SiPM PET/CT

EDITORIAL

More evidence for prognostic value of quantification of myocardial perfusion

ORIGINAL ARTICLE

Decline in typical angina among patients referred for cardiac stress testing

Images that Teach

PET myocardial perfusion imaging in superior vena cava syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits